Belenkov Yu N, Tsvetkova O A, Privalova E V, An G V, Ilgisonis I S, Voronkova O O
I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University).
Kardiologiia. 2019 Jun 25;59(6):48-55. doi: 10.18087/cardio.2019.6.n458.
Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients' mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.
慢性阻塞性肺疾病（COPD）是全球第四大致死原因。96%的COPD患者存在合并症。其中最重要的是心血管疾病（冠状动脉疾病、动脉高血压、慢性心力衰竭），每三例COPD患者死亡中就有一例与之相关。COPD和心血管疾病有共同的危险因素和发病机制。心脏选择性β受体阻滞剂可降低COPD的发病风险和加重频率，治疗COPD患者有效且安全。
